Summary This report reviews 48 patients who from 1979 to 1994 were treated at the Norwegian Radium Hospital for newly diagnosed noncerebral extragonadal malignant germ cell tumour (EGGCT). Based on histology and/or serum tumour markers, 12 patients had a seminoma and 36 a non-seminoma. At diagnosis, 33 and 15 patients were classified as having abdominal and mediastinal EGGCT respectively. At the time of diagnosis 13 patients, all with non-seminomatous tumours, had metastases to bone, liver or brain. One patient with abdominal seminoma was cured by radiotherapy alone, whereas cisplatin-based chemotherapy (with or without surgery) was planned in the 47 remaining patients. Twenty-seven out of 42 patients receiving four or more chemotherapy cycles were rendered tumour free by induction chemotherapy, including 5 of the 13 patients with extralymphatic non-pulmonal disease. An additional tumour-free patient died of septicaemia after only two cycles of chemotherapy. Late relapses (after > 2 years) were observed in three patients, and a testicular primary was diagnosed during follow-up in three cases. Seven patients died of treatment-related complications, five of these because of neutropenic septicaemia. The median age of these patients was 52 years compared with 35 years in the remaining 41 patients (P < 0.05). The 5-year overall survival for all 48 patients was 60% (95% Cl 46-74%) [cancer-specific 5-year survival 71% (95% Cl 50-92%)]. EGGCT is a potentially curable disease, even in patients with very advanced disease. Special attention should, however, be devoted to patients above the age of 40 years because of an increased risk of treatment-related side-effects. Late relapses and the subsequent development of testicular tumours indicate the need for long-term follow-up.
Germ cell malignancy, most often presenting as testicular cancer, is the most common malignancy in young adult men aged 15-35 years, and the incidence of testicular cancer is increasing. Extragonadal germ cell tumour (EGGCT) is a rare subgroup of germ cell malignancy mostly affecting men, although it may also be diagnosed in women. EGGCTs are most frequently detected in mediastinum and retroperitoneal lymph nodes, but have also been described in the central nervous system (Johnson et al, 1973) , liver (Hart, 1975) and prostate gland (Dvoracek, 1949) . The pathogenesis of EGGCT remains unknown. It has been suggested that there is a pathogenetic difference between mediastinal and retroperitoneal manifestation of EGGCT (Nichols et al, 1987) . More recent observations, however, indicate the mediastinal EGGCT and primary testicular cancers may be cytogenetically similar (Chaganti et al, 1994) suggesting the same origin for all germ cell tumours. Daugaard et al (1992) have reported that biopsies from testis in patients with retroperitoneal EGGCT showed testicular carcinoma in situ (CiS) in 42% of the patients (Daugaard et al, 1992) . According to those authors, testicular CiS was not found in any of the eight patients with mediastinal EGGCT. Based on these findings, the hypothesis was put forward that some cases of retroperitoneal EGGCT may be due to a primary testicular cancer with metastases to the retroperitoneal lymph nodes and subsequent necrosis of the primary tumour, thus finally presenting as EGGCT.
Testicular cancer has become a model of a curable metastatic solid malignant tumour. In most reports, the survival rates of patients with EGGCT are, however, inferior compared with those of patients with advanced testicular cancer, although the treatment regimens are often the same for both conditions.
In this report, we describe the findings at the time of diagnosis and the outcome of all 48 patients diagnosed and treated for EGGCT at the Norwegian Radium Hospital (NRH) during the period 1979-95, i.e. from the time when cisplatin-based chemotherapy became available in Norway.
PATIENTS AND METHODS Patients
This series comprises all 48 patients treated for EGGCT at the Norwegian Radium Hospital (NRH) between 1979 and 1994. Thirty-six patients treated within 1991 had previously been entered into the series of the Intemational Germ Cell Cancer Collaborative Group (IGCCCG) (International Germ Cell Cancer Collaborative Group, 1997) . Forty-three cases were classified as extragonadal germ cell tumours by malignant germ cell histology of a mid-line tumour. In five patients with mid-line tumours, * Non-pulmonary visceral metastases * AFP < 1000 ng ml-' and * AFP > 1000 and < 10 000 IUll or * AFP > 10 000 ng 1-' or HCG < 1000 ng ml-' and HCG . 5000 IU I-' and < 50 000 IU -11 or HCG > 50 000 IU 1-1(1 00 000 ng ml-' or LDH < 1.5 x upper limit of normal LDH . 1.5 x N and < N and 10 x N LDH > 10 (Fossa et al, 1988 ; Lewis et al, 1991) . The type of primary treatment and the number of cycles of chemotherapy given are summarized in Table 2 . Because of the advanced stage in many of these patients with EGGCT, rather intensive chemotherapy schedules were frequently selected. In general, the application of at least four cycles were planned in each patient. If after four or more chemotherapy cycles the serum tumour markers were normal or had reached a plateau, but residual masses were detectable in the absence of new lesions, post-chemotherapy resection of these masses was principally scheduled in patients with non-seminoma, but not in those with seminoma.
Response
At the end of the initial treatment containing at least four chemotherapy cycles, three response categories were identified.
Complete response
Complete response required the normalization of clinical, radiological and serological findings by chemotherapy alone or after post-chemotherapy resection of residual masses. Histology of such masses could either be fibrosis/necrosis, mature or viable malignant tumour. (There was no patient with residual viable malignant tumour with only a biopsy or an incomplete resection.)
Inevaluable for response A patient was inevaluable for response when there was the persistence of unbiopsied and unresectable tumour masses in the presence of normal tumour markers. 
Response
One patient with abdominal seminoma was rendered tumour free by radiotherapy alone. Twenty-seven of 42 patients receiving four or more chemotherapy cycles showed a complete response. Among these complete responders, there were five (out of 13) patients, who initially presented with metastases to the brain, liver or bones. Two further patients were recorded to be tumour free after post-chemotherapy surgical excision of viable cancer tissue. Four patients were inevaluable for response, whereas progression was recorded in nine patients. The remaining five patients were non-assessable for response as they received three or less chemotherapy cycles. One of them was, however, tumour free at autopsy, which was performed after he had died because of septicaemia after his second cycle.
Relapse and salvage treatment
Four of the 30 completely responding patients relapsed as did all four patients who were inevaluable for response at the end of primary chemotherapy. The former four cases included both patients in whom viable malignant tumour tissue was resected. They could not be salvaged by available chemotherapy (Hollender et al, 1997) . Two other patients relapsing after initial complete response became tumour free, but both developed a second relapse 7 and 9 years after this first salvage treatment. Two of the four patients inevaluable for response progressed shortly after their initial chemotherapy and were not salvaged. The third patient with the mediastinal seminoma responded completely to repeated chemotherapy and radiotherapy, but developed a second incurable relapse 3 years thereafter. In the fourth patient with inevaluable response, the residual mediastinal tumour increased in size 3 years after chemotherapy discontinuation. The subsequent resection of the tumour revealed a growing mature teratoma. He has remained without evidence of disease thereafter. (Figure 2 ), the respective figures for 5-year cancer-specific survival being 80% (95% CI 62-98%) and 62% (95% CI 41-63%) (Figure 3 ).
Toxic deaths
A total of seven patients died because of treatment-related complications (Table 4 scheduled chemotherapy cycle before any cytostatic drugs were given. Three patients (nos 4, 6 and 7) died after the first cycle and one (no. 2) after two cycles because of chemotherapy-induced neutropenic septicaemia. These patients received chemotherapy before granulocyte colony-stimulating factor (G-CSF) was available. The remaining two patients received four and five cycles. They underwent post-chemotherapy surgery for residual mediastinal masses, but died of post-operative complications. Two of the seven patients who died of treatment-related complications (patients no. 2 and 6) were tumour free based on the histological examination of the operation specimen or on the results of autopsy. The median age of the seven patients with fatal treatment-related complications was 52 years compared with 33 years for the remaining 41 patients (P < 0.05). Only one of the seven patients who died of treatmentrelated causes was below the age of 40 years. The ages of the four patients who died of septicaemia after receiving only 1 or 2 cycles of chemotherapy were 47, 51, 70 and 76 years.
Subsequent testicular cancer
Three patients developed an invasive testicular cancer 3, 10 or 11 years after the diagnosis of EGGCT. In the two patients with an abdominal non-seminomatous EGGCT, the subsequent testicular histology revealed a pure seminoma in one case and non-seminoma in the other. The third patient with an initial mediastinal pure seminoma (without abdominal manifestations) developed a stage II non-seminoma 3 years after the diagnosis of EGGCT and simultaneous testicular carcinoma in situ of his left testicle. (His maldescent right testicle had been removed during puberty.)
DISCUSSION
In this report, we describe the clinical course of 48 cases with extragonadal extracerebral germ cell tumours diagnosed over a period of 15 years in a geographically defined area ('Health region II') of about 1.5 million people. Our study comprises all patients seen at the NRH during this period, including a patient who died after only having received prehydration before any chemotherapy was administered. All patients with this diagnosis in our Health region were referred to the NRH. Our experience therefore indicates an incidence of extragonadal germ cell tumour of 0.5 per 100 000 per year. This represents about 2% of the number of testicular cancer patients in the same population during the same time period.
It has been suggested that mediastinal and retroperitoneal EGGCTs have different pathogenesis and tumour biology, the former sometimes combined with haematological malignancies at One cycle Neutropenic septicaemia 11 days CVB aPlanned high-dose cisplatin-based chemotherapy. the time of diagnosis or after treatment (Nichols et al, 1985 (Nichols et al, , 1987 . This is in agreement with the observation of histocytosis in one of our patients with malignant mediastinal EGGCT. Recently, it has also been suggested that some retroperitoneal EGGCTs may represent metastases from a testicular cancer with subsequent spontaneous necrosis of the primary tumour (Daugaard et al, 1992) . On the other hand, Chaganti et al (1994) suggested the same origin of all germ cell tumours based on cytogenetic studies. In our series, only about 40-50% of the tumours were confined to either mediastinum or to the abdomen, making it at times difficult to clearly determine an abdominal or mediastinal origin.
At the time of presentation, most of the patients have advanced disease, 29% of our patients presenting with extrapulmonary haematogeneous spread. Many clinical investigators consider patients with EGGCT to have a poor prognosis without taking into account the extent of disease. Although it is true that the survival of these patients is below that of patients with testicular cancer (Feun et al, 1980; Gonzalez-Vela et al, 1992) , only about half of our patients with EGGCT belonged to the IGCCCG poor-prognosis group. As in the IGCCCG series, patients with a seminomatous EGGCT generally had a more favourable diagnosis than those with a non-seminomatous tumour.
The pretreatment establishment of a specific histological diagnosis may sometimes be difficult in patients with EGGCT, particularly as treatment often has to be started in an emergency situation. The determination of germ cell tumour serum markers (HCG, AFP) is critical for the diagnosis of EGGCT and subtyping. Often, high serum markers have to be taken as proof of germ cell malignancy in the case of mid-line tumours in younger patients. Using these guidelines, the ratio of seminoma to non-seminoma in our patient population was 1:3. Others have reported ratios from 1:1.1 to 1:2.5 (Gutierrez Delgado et al, 1993; Goss et al, 1994; Gerl et al, 1996) . All patients with haematogeneous metastases to extrapulmonary organs had a non-seminoma, indicating the tendency of these tumours to metastasize to brain, bone or liver compared with seminoma.
Our results indicate that even patients with far-advanced extragonadal germ cell tumours can be cured by intensive chemotherapy with a 5-year overall survival of 60% and a 5-year cancer-specific survival of 71 %. Of the 28 patients with a complete response to chemotherapy (27) or radiotherapy (one), 27 are alive. These figures are higher than reported by two other groups (Gonzalez-Vela et al, 1992; Gutierrez Delgado et al, 1993) , but similar to results published by Goss et al (1994) . In contrast to these results, none of 11 patients who had progressed at the end of primary chemotherapy treatment or had viable tumour cells in post-chemotherapy biopsies was durably salvaged by second-line treatment. This low cure rate is similar to that reported by others (Saxman et al, 1994; Gerl et al, 1996) for similar EGGCT patients.
The median age of our patients with extragonadal germ cell tumours was 35 years, which is about 10 years older than reported in the literature (Gonzalez-Vela et al, 1992; Goss et al, 1994) . The high median age of our patients may explain our relatively high rate of deaths because of complications. In particular, our observations suggest that the risk of fatal neutropenic septicaemia increases with higher age. In 'older' patients, the bone marrow may be less functional than in younger patients with advanced germ cell malignancies. Special attention and care should therefore be devoted to these 'older' patients with EGGCT during chemotherapy. G-CSF should probably be administered at an early phase of their treatment to avoid complications as a result of reduced bone marrow function.
For the clinician, it is important to be aware of the possibility of late recurrences (2 2 years after treatment discontinuation) as seen in 3 of 32 patients at risk. Furthermore, patients with EGGCT may develop testicular tumours many years after their initial diagnosis, as also pointed out by Daugaard et al (1987) and Gerl et al (1996) . These clinical observations suggest multicentricity of the germ cell malignancy, at least in some patients.
In summary, patients with extragonadal germ cell tumours often present with far advanced tumour manifestations. However, only about 50% of the consecutive patients seen at a major oncology centre belonged to the poor-prognosis group as defined by the IGCCCG. EGGCT is sensitive to cisplatin-based chemotherapy and patients should be treated with intention to cure, even when presenting with metastases to bone, liver or brain. An overall 5-year survival of 60% was obtained with a cancer-specific 5-year survival of 71%. Recurrences and new manifestations of germ cell malignancy may develop after several years. Intensive cisplatinbased chemotherapy of these patients with widespread metastases carries a considerable risk of severe treatment-related complications, in particular, of neutropenic septicaemia in patients over the age of 40 years.
